CA2306276A1 - Compose actif du point de vue pharmaceutique et ses methodes d'utilisation - Google Patents

Compose actif du point de vue pharmaceutique et ses methodes d'utilisation Download PDF

Info

Publication number
CA2306276A1
CA2306276A1 CA002306276A CA2306276A CA2306276A1 CA 2306276 A1 CA2306276 A1 CA 2306276A1 CA 002306276 A CA002306276 A CA 002306276A CA 2306276 A CA2306276 A CA 2306276A CA 2306276 A1 CA2306276 A1 CA 2306276A1
Authority
CA
Canada
Prior art keywords
compound
chloro
mammal
effective amount
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002306276A
Other languages
English (en)
Inventor
James B. Fischer
Seetharamaiyer Padmanabhan
Graham J. Durant
Michael Perlman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cenes Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2306276A1 publication Critical patent/CA2306276A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43—Y being a hetero atom
    • C07C323/44—X or Y being nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)

Abstract

La présente invention concerne N-(2-chloro-5- méthylthiophényl) -N'-(3-méthylsulfinylphényl) -N'-méthylguanidine, N-(2-chloro-5- méthylsulfinylphényl) -1-(7-trifluorométhyl -1,2,3,4- tétrahydroquinolinyl) carboximidamide, et N-(3-méthylsulfinylphényl) -N-méthyl-N'- (2-chloro-5-méthoxyphényl) guanidine, ainsi que leurs sels acceptables du point de vue pharmaceutique, des compositions pharmaceutiques et des méthodes thérapeutiques de traitement comprenant ces composés. Les composés de l'invention sont particulièrement utiles pour le traitement ou la prophylaxie de lésions neurologiques et de troubles neurodégénératifs.
CA002306276A 1997-10-10 1998-10-09 Compose actif du point de vue pharmaceutique et ses methodes d'utilisation Abandoned CA2306276A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6346997P 1997-10-10 1997-10-10
US60/063,469 1997-10-10
PCT/US1998/021395 WO1999018962A1 (fr) 1997-10-10 1998-10-09 Compose actif du point de vue pharmaceutique et ses methodes d'utilisation

Publications (1)

Publication Number Publication Date
CA2306276A1 true CA2306276A1 (fr) 1999-04-22

Family

ID=22049424

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002306276A Abandoned CA2306276A1 (fr) 1997-10-10 1998-10-09 Compose actif du point de vue pharmaceutique et ses methodes d'utilisation

Country Status (6)

Country Link
EP (1) EP1041986A4 (fr)
JP (1) JP2001519393A (fr)
KR (1) KR100761451B1 (fr)
AU (1) AU1076799A (fr)
CA (1) CA2306276A1 (fr)
WO (1) WO1999018962A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309791T1 (de) * 1999-09-15 2005-12-15 Alza Corp Transdermale verabreichung von n-(2,5 disubstituierten phenyl)-n'-(3 substituierten phenyl)-n'-methyl guanidinen
GB201008047D0 (en) 2010-05-14 2010-06-30 Ge Healthcare Ltd Method of synthesis

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0705100T3 (da) * 1993-05-27 2003-11-17 Cenes Ltd Terapeutiske substituerede guanidiner
KR19990082494A (ko) * 1996-02-15 1999-11-25 버틀러 그레고리 비. 약학적 활성 화합물 및 이의 사용 방법

Also Published As

Publication number Publication date
WO1999018962A1 (fr) 1999-04-22
JP2001519393A (ja) 2001-10-23
AU1076799A (en) 1999-05-03
KR20010031007A (ko) 2001-04-16
KR100761451B1 (ko) 2007-09-27
EP1041986A4 (fr) 2001-03-21
EP1041986A1 (fr) 2000-10-11

Similar Documents

Publication Publication Date Title
KR940010764B1 (ko) 페닐카르바메이트 및 이것의 염을 제조하는 방법
CZ304702B6 (cs) (4R) a (4S) diastereoizomery (2S)-2-[2-oxo-4-propylpyrrolidinyl] butanamidu, farmaceutická kompozice s jejich obsahem a jejich použití
JPWO1998047505A1 (ja) 神経ペプチドｙ受容体拮抗剤
US5240933A (en) 14-hydroxy-n-(2-methoxyethyl)-7,8-dihydromorphine and -norisomorphine, processes for the preparation thereof and the use thereof as pharmaceutical compositions
EP1242069B1 (fr) Composes liant l'albumine qui empechent la glycation non enzymatique et qui peuvent etre utilises dans le traitement de pathologies liees a la glycation
EP2852571A2 (fr) Compositions et méthodes pour le traitement de la mucosite
KR100424523B1 (ko) 치료용의치환된구아니딘
EP4074696B1 (fr) N-[4-(6-fluoro-3,4-dihydro-2(1h)-isoquinolinyl)-2,6-diméthylphenyl]-1-méthyl-cyclopropane-acetamide, un régulateur du canal potassique pour le traitement d'épilepsie
JPH0372467A (ja) ピペラジン誘導体
EA015745B1 (ru) Соединения, проявляющие активность в отношении св
RU2300532C2 (ru) Производные бензо[g]хинолина для лечения глаукомы и близорукости, способ их получения и фармацевтическая композиция
CA2872975A1 (fr) Compositions et methodes de traitement de troubles neurologiques
CA2306276A1 (fr) Compose actif du point de vue pharmaceutique et ses methodes d'utilisation
US6774263B1 (en) Pharmaceutically active compound and methods of use
JPH0770013A (ja) β３ −アドレナリン作動薬として作用する｛（７Ｓ）−７−［（２Ｒ）−２−（３−クロロフェニル）−２−ヒドロキシエチルアミノ］−５，６，７，８−テトラヒドロナフタレン−２−イルオキシ）酢酸及びその薬学的に許容されうる塩、並びにそれらが存在する薬学的組成物及び研究室用試薬
EP2847197A1 (fr) Promédicaments d'agents antiplaquettaires
US20040127505A1 (en) Serotonergic Agents with long-acting in vivo effects
OA11350A (en) Dofetilide polymorphs.
US20030069274A1 (en) Pharmaceutically active compounds and methods of use
AU777920B2 (en) Beta-D-5-thioxylose derivatives, preparation method and therapeutic use
JP2798628B2 (ja) 癲癇治療用の５−アミノカルボニル−５Ｈ−ジベンゾ［ａ，ｄ］シクロヘプテン−５，１０−イミン
US5196415A (en) 5-aminocarbonyl-5H-dibenzo[a.d]cyclohepten-5,10-imines for treatment of epilepsy and cocaine addiction
US5239110A (en) Phenylcyclohexanol derivatives as agents for treating CNS disorders
WO2014060941A2 (fr) Compositions d'agents neuroprotecteurs et procédés correspondants destinés au traitement de maladies neurologiques et neurodégénératives
WO2014049471A1 (fr) Compositions et procédés destinés au traitement d'arythmies ventriculaires et de maladies cardiovasculaires

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead